The headline news is that Celgene chief executive Mark Alles is heading for the door, and there’s also no room for BMS’ recently-appointed chief scientific officer Thomas Lynch in the combined ...

Opdualag – which combines the PD-1 inhibitor nivolumab in BMS' blockbuster cancer drug Opdivo with LAG-3 inhibitor relatlimab – was unable to improve on Opdivo alone in the RELATIVITY-098 ...